PARP inhibitor re-sensitizes Adriamycin resistant leukemia cells through DNA damage and apoptosis

Resistance to Adriamycin (ADR) is an increasing problem in the treatment of leukemia and the development of novel therapeutic strategies is becoming increasingly important. Olaparib is a poly (adenosine diphosphate-ribose) polymerase (PARP) 1 inhibitor, which has promising antitumor activity in pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jie, Xiao, Sheng, Yuan, Miaomiao, Li, Qianyuan, Xiao, Guangfen, Wu, Wei, Ouyang, Yuexian, Huang, Lihua, Yao, Chenjiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297734/
https://www.ncbi.nlm.nih.gov/pubmed/30431088
http://dx.doi.org/10.3892/mmr.2018.9628

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6297734/
https://www.ncbi.nlm.nih.gov/pubmed/30431088
http://dx.doi.org/10.3892/mmr.2018.9628

Ejemplares similares